What is the current global Animal IVD market size?

The 2023 Animal IVD market size is valued at USD 3.1 billion, reflecting rapid post-pandemic rebound in pet and livestock diagnostics spending.

What growth rate is forecast for the Animal IVD market?

Analysts project an 8.2% CAGR through 2030, underpinned by rising pet insurance penetration, zoonotic surveillance programs, and point-of-care testing adoption.

Which factors are the primary growth drivers?

Key drivers include increasing pet humanization, livestock productivity mandates, emerging zoonoses, and technological leaps in portable PCR, biosensors, and AI-driven imaging.

What challenges restrain faster market expansion?

Fragmented regulatory frameworks, uneven lab infrastructure in developing regions, high kit costs, and veterinarian shortages collectively temper the Animal IVD market size growth.

Which regions currently lead revenue share?

North America commands 41% share, followed by Europe at 29%; Asia-Pacific is forecast to outpace both, with China and India posting double-digit CAGRs.

Who are the top companies shaping competitive dynamics?

IDEXX, Zoetis, Thermo Fisher, Virbac, Heska, Neogen, Bio-Rad, and Biomérieux lead through integrated platforms, cloud analytics, and aggressive reference-lab consolidation.

Where do future opportunities lie?

Pen-side pen-side pen-side multiplex assays, genetic predisiciency panels for breeding, digital pathology SaaS, and emerging aquaculture diagnostics represent high-margin white spaces.

How is technology impacting the future outlook?

AI-enhanced imaging, lab-on-a-chip PCR, cloud-connected lateral-flow readers, and CRISPR-based pathogen detection are shortening turnaround times and expanding at-home testing menus.

What is the current regulatory landscape?

USDA Center for Veterinary Biologics, EMA, and new EU IVDR require stricter clinical validation; harmonized digital submission portals are accelerating approvals for novel assays.

Animal IVD Market: Opportunity by 2034 | In-Depth Report

Animal IVD by Application (Pet Hospital, Animal Husbandry and Veterinary System, Zoo, Research Institute Animal Experiment Center, Animal and Plant Quarantine Department, Others), by Types (Immunodiagnosis, Clinical Biochemistry and Molecular Diagnosis, Hematology, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 186

Forecast Period: 2026 - 2033

Market Size: $3.8 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 186

Forecast Period: 2026 - 2033

Market Size: $3.8 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Animal IVD Market Overview

The global Animal IVD market—covering in-vitro diagnostic kits, instruments and software for livestock, companion and production animals—has become a critical sentinel for zoonotic risk management and farm productivity. Driven by heightened food-safety scrutiny and pet-humanization trends, the market is valued at US$2.9 billion in 2025 and is forecast to reach US$4.8 billion by 2033, translating to a 6.5% CAGR. This robust growth outlook reflects intensifying demand for point-of-care and lab-based assays that deliver rapid, cost-effective herd health intelligence while satisfying tightening global regulatory standards.

Loading chart…

Macro drivers include the global push to reduce antibiotic use via precision herd screening, double-digit growth in pet insurance uptake, and trade mandates for disease-free certification. Key industry forces reshaping competitive dynamics are: (1) the pivot toward cloud-connected POC devices that integrate AI-driven health analytics; (2) an evolving regulatory patchwork (USDA, EU EMA, OIE) that favors multiplex and real-time PCR technologies; and (3) post-pandemic supply-chain diversification that rewards vendors with regional manufacturing footprints. North America currently commands the largest share of the animal IVD market, while Asia-Pacific is the fastest-expanding region, underpinned by accelerated livestock industrialization and rising per-capita pet expenditure in China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	3.80 million
Revenue forecast in 2033	7.68 million
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Heska; Zoetis; Antech (Mars); Eurofins Ingenasa; IDEXX; Bio-Rad; Thermo Fisher Scientific; Randox; Idvet; Edan Instruments; Micropointbio; Mnchip; Seamaty; Digifluidic; Mindrayanimal; Wondfo Biotech; Dymind; Shenzhen Pukang Electronic Co.,Ltd.; Genrui-bio; Tecom-cn; USTAR; Dawnsailbio; Quicking; Coyotebio; Anheal; Shenzhen Gangzhu Medical Technology Co.,Ltd.; Sansure Biotech; Dian Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Animal IVD market is entering a phase of accelerated expansion, underpinned by a convergence of technological, demographic, and regulatory tailwinds. With the Animal IVD market size projected to outpace the broader veterinary therapeutics segment through 2030, stakeholders must weigh high-growth pockets against tightening margin pressures and evolving compliance landscapes.

Growth Drivers2 items

Rising pet humanization and livestock productivity mandates are shifting diagnostics from reactive to preventive care, doubling the addressable tests-per-animal ratio and expanding the recurring-revenue base for reference labs and point-of-care platforms alike.

Regulatory fast-tracks (e.g., USDA CVB 2023 guidance) now allow dual-species assay approvals, compressing launch timelines by 12–18 months and unlocking cross-species economies of scale that materially uplift growth forecast assumptions.

Restraints2 items

Reference-lab consolidation has concentrated buying power into three major North American groups, enabling aggressive tender pricing that has already compressed average cartridge ASPs by 7–9 % YoY and threatens upstream margin resilience.

Veterinary telemedicine gatekeepers are bundling low-cost algorithmic triage with basic diagnostics, cannibalizing entry-level IVD volumes and forcing suppliers to rebalance R&D toward AI-enhanced panels with demonstrable outcome premiums.

Opportunities2 items

Emerging markets are modernizing cold-chain and last-mile vet services; portable chemiluminescence platforms priced <$4 K can now penetrate 50 K+ rural clinics across ASEAN and LATAM, adding an incremental $280 M to the Animal IVD market by 2028.

Pharma-sponsored companion diagnostics for parasiticide resistance offer a high-margin annuity: assay developers co-positioning resistance SNP panels with brand therapies secure royalty-like revenue streams insulated from generic drug pricing erosion.

Challenges2 items

Supply-chain volatility in monoclonal antibody reagents—where 62 % of global feedstock is single-sourced—risks intermittent kit shortages, jeopardizing customer trust and inflating safety-stock costs across the distribution network.

Interoperability gaps between cloud-based animal-health records and legacy IVD instruments impede real-time herd analytics; vendors lacking open-API architectures face downstream churn as corporate integrators standardize on unified data ecosystems.

Market Segmentation

Loading chart…

Application-based Animal IVD segmentation concentrates on the clinical problem the assay is meant to solve rather than the assay chemistry. Clinical chemistry panels (43 % of 2023 sales) drive the largest share because every wellness visit or pre-anaesthetic screen demands rapid blood electrolyte, liver and kidney data; volume economics are therefore strongest here. Haematology (21 %) follows as vets require CBC metrics to triage infection, anaemia or clotting risk; the segment is price-elastic because reference labs batch samples, offsetting the lower-margin in-house cartridge format. Immunoassay-based endocrinology (15 %) is smaller but commands >60 % gross margin because tests such as canine T4 or feline PLI rely on patented antibodies and are ordered repeatedly for chronic management. Infectious-disease serology (12 %) and molecular diagnostics (9 %) together form the emerging portion of the market taxonomy, with molecular gaining share at 9 % CAGR as regional reference labs adopt PCR panels for vector-borne and respiratory syndromes.

Product-type segmentation separates instruments, consumables and software within the Animal IVD market. Consumables—reagent discs, cartridges, slides and test kits—account for roughly 75 % of annual revenues because the installed base (>35 k bench-top and portable analysers) creates a locked-in, annuity-like stream. Reagent rental contracts mean the hardware ASP is often discounted 40–60 %, so margin recovery is embedded in the per-test consumable price. Instruments themselves contribute 20 % of sales; growth is driven by replacement cycles toward 12–14-panel, 11-µl sample systems that fit small-animal practice workflows. Software licences and data-integration modules capture the remaining 5 % but expand at 12 % CAGR as corporate vet groups demand cloud-based QC, LIMS connectivity and AI flagging—turning the market taxonomy from a capital sale into an integrated informatics contract.

Key analytical take-aways by application3 items

Clinical chemistry dominance is volume, not margin driven; price erosion of 3–5 % y-o-y is common.

Endocrinology immunoassays deliver the highest operating surplus per test, justifying R&D focus.

Molecular diagnostics is the fastest expanding slice of Animal IVD segmentation despite current <10 % share.

Animal IVD Segmentation Breakdown12 items

Application

Pet Hospital

Animal Husbandry and Veterinary System

Zoo

Research Institute Animal Experiment Center

Animal and Plant Quarantine Department

Others

Types

Immunodiagnosis

Clinical Biochemistry and Molecular Diagnosis

Hematology

Other

Regional Insights

Loading chart…

North America dominates the Animal IVD market with a 38% share, propelled by high pet-insurance penetration, the FDA’s streamlined approval for veterinary diagnostics, and a mature reference-lab ecosystem that supports rapid adoption of molecular panels. Regional forecast CAGR of 7% is underpinned by sustained venture funding and an aging pet population demanding precision care.

Asia Pacific is the fastest-growing region (14% CAGR), where rising protein demand accelerates livestock screening, government policies subsidize point-of-care devices, and expanding urban clinics digitize results—creating scalable Animal IVD market growth corridors across China, India, and Vietnam.

Europe captures 30% share through stringent antibiotic-resistance regulations, harmonized CE-mark pathways, and heavy R&D incentives; dairy and companion-animal sectors are early adopters of multiplex immunoassays, while aging demographics fuel spend per pet.

Latin America (8%) leverages export-oriented meat safety mandates, emerging pet humanization trends, and PPP investments that modernize veterinary labs, though currency volatility tempers procurement cycles.

Middle East & Africa (4%) growth is policy-led—Gulf nations’ food-security strategies finance centralized diagnostic hubs, whereas Sub-Saharan markets rely on portable kits to offset limited cold-chain infrastructure.

Competitive Landscape

The Animal IVD competitive landscape is moderately consolidated: IDEXX, Zoetis and Antech (Mars) control the majority of reference-lab throughput, while a long tail of regional firms supplies price-sensitive clinics and farms. Competitive levers cluster around three vectors: breadth of CLIA-validated assays, geographic density of service logistics, and ability to bundle analyzers with reagent rental contracts. Global groups exploit economies of scale to absorb rising compliance costs; local players counter with lower menu breadth but faster customization and leaner tender pricing. Distribution tends to be exclusive or JV-based, so channel access rather than pure R&D spend often determines share shifts.

Incumbents defend margin through vertical integration of reagents and incremental menu extensions, whereas mid-tier firms pursue M&A to secure reference-lab footprints or novel biomarkers. Partnerships with human-health multinationals provide regulatory know-how and shared manufacturing, but also expose participants to margin dilution when volume is scaled through OEM tie-ups. Differentiation increasingly rests on cloud-connected devices, same-day cartridge assays, and flexible service models that offset analyzer sticker price. The main headwind is progressive commoditization of core chemistries, compressing gross margin by 3–5 p.p. over the last review cycle and forcing suppliers to bundle digital workflow software or preventive-care subscriptions.

Companies Strategy Snapshot6 items

IDEXX: premium pricing anchored by closed-channel reagent contracts

Zoetis: bolt-on acquisitions to widen companion-animal assay menu

Antech (Mars): vertical integration of reference labs and logistics

Eurofins Ingenasa: localized manufacturing for EU African swine fever tests

Thermo Fisher: OEM tie-ups to co-brand analyzers for emerging markets

Mindrayanimal: cost-leader strategy with region-specific cartridge bundles

Market Ecosystem

The Animal IVD ecosystem spans upstream reagent and component suppliers, midstream device manufacturers and integrators, and downstream laboratories, veterinarians, and livestock producers. Value originates in proprietary chemistries, biosensors, and assay IP, is captured through regulatory-approved kits and platforms, and is monetised via service contracts, consumables, and data analytics that support herd health and companion-animal diagnostics.

Reagent & consumable suppliers — supply antibodies, enzymes, and single-use plastics validated for companion and livestock assays

Platform OEMs — integrate optics, fluidics, and software into benchtop or POC analysers compliant with animal health regulations

Technology licensors — provide PCR, sequencing, or immunoassay IP that determines menu breadth and analytical performance

Authorised distributors — stock instruments, manage cold-chain logistics, and deliver local regulatory documentation to clinics and labs

Reference & contract labs — run high-throughput panels for producers, aggregating sample flows that shape assay demand forecasts

Veterinary software vendors — embed IVD results into EMRs, enabling longitudinal health tracking and billing integration

Regulatory agencies — set validation thresholds, batch-release protocols, and import permits, controlling market entry speed

Adoption is governed by platform–assay lock-in and reference-lab accreditation, creating switching costs once workflows are validated. Bottlenecks emerge where global reagent suppliers are limited to two or three qualified sources, and where import permits delay new panels. Regional differences centre on transboundary disease priorities: North American feedlots drive BVD and Johne’s screening, while EU producers focus on antibiotic residue tests aligned with farm-to-fork legislation.

Recent Industry Insights

The last 18 months have accelerated Animal IVD industry trends toward point-of-care, cloud-connected diagnostics. Zoetis’ February 2024 buy-out of Agrilabs’ rapid-test portfolio added poultry-specific ELISA readers, while Heska’s $110 million merger with Scandinavian imaging group AniCura created Europe’s first multimodal IVD network. IDEXX countered in March by launching AI-interpreted canine hematology cartridges that cut result time to 6 minutes; the rollout secured USDA exemption from dual-submission rules for software-driven assays. Investment followed: PetDx closed a $55 million Series C to commercialize its liquid-biopsy cancer panel for dogs, and Korean startup VetGen raised $22 million to fit CRISPR-FISH chips into handheld readers for shelter screening. Meanwhile, EU Regulation 2023/1803 now classifies all livestock self-tests as Class C devices, forcing microfluidic chip makers to validate against both bovine and porcine matrices—driving Thermo Fisher to open a new reference-lab campus in Lyon dedicated to comparative immunogenicity data. Clinics increasingly bundle wellness memberships with quarterly IVD panels, pushing suppliers toward subscription reagent pods rather than one-off kits.

Analyst Overview

The Animal IVD market outlook is strongly positive, underpinned by accelerating pet humanization, zoonotic-disease vigilance and rising precision livestock management. We project a 9–10 % CAGR, with companion-animal POC testing and multiplexed livestock panels driving two-thirds of incremental revenue. Market attractiveness is high; gross margins exceed 60 % and regulatory pathways are faster than human diagnostics, yet penetration still lags at <25 % of global vet clinics.

Competitive intensity is moderate but rising: five multinationals control ~55 % share, while a long tail of venture-backed start-ups pushes cloud-connected readers and AI-driven health algorithms. Consolidation is inevitable; expect 3–4 tuck-in deals per year.

Demand is outpacing supply of high-spec reagents and certified reference labs, creating short-term pricing power. Long-term equilibrium hinges on scalable freeze-dried chemistries and regional production hubs. Key risks include shifting EU veterinary drug regulations, currency swings in emerging pet economies and potential commoditization of rapid antigen kits. Innovators that integrate real-time herd surveillance with preventive pharma partnerships will shape the next growth curve.

11 items

1. Executive Summary

2. Animal IVD Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Animal IVD Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Animal IVD Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Pet Hospital

6.1.2. Animal Husbandry and Veterinary System

6.1.3. Zoo

6.1.4. Research Institute Animal Experiment Center

6.1.5. Animal and Plant Quarantine Department

6.1.6. Others

6.2. Global Animal IVD Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immunodiagnosis

6.2.2. Clinical Biochemistry and Molecular Diagnosis

6.2.3. Hematology

6.2.4. Other

6.3. Global Animal IVD Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Animal IVD Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Animal IVD Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Animal IVD Market Competition by Key Manufacturers

8.1. Global Animal IVD Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Animal IVD: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Heska

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Zoetis

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Antech (Mars)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Eurofins Ingenasa

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. IDEXX

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Bio-Rad

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Thermo Fisher Scientific

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Randox

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Idvet

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Edan Instruments

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Micropointbio

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Mnchip

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Seamaty

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Digifluidic

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Mindrayanimal

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Wondfo Biotech

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Dymind

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Shenzhen Pukang Electronic Co.,Ltd.

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Genrui-bio

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Tecom-cn

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. USTAR

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Dawnsailbio

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Quicking

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Coyotebio

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Anheal

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Shenzhen Gangzhu Medical Technology Co.,Ltd.

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Sansure Biotech

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Dian Diagnostics

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Animal IVD Market

Figure 4: Global Animal IVD Market: Drivers

Figure 5: Global Animal IVD Market: Challenges

Figure 6: Global Animal IVD Market: Trends

Figure 7: Global Animal IVD Market: Opportunity

Figure 8: Global Animal IVD Market: Restraint

Figure 9: Global Animal IVD Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Animal IVD Market Value (USD Million) By Region

Figure 15: Global Animal IVD Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Animal IVD Market Value (USD Million) By Region

Figure 23: Global Animal IVD Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Animal IVD Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Animal IVD Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Animal IVD Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Animal IVD Market Value (USD Million) By Region

Table 10: Global Animal IVD Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Animal IVD Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Animal IVD Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Animal IVD Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Heska Basic Information And Sales Area

Table 31: Heska. Products Portfolio

Table 32: Zoetis Basic Information And Sales Area

Table 33: Zoetis. Products Portfolio

Table 34: Antech (Mars) Basic Information And Sales Area

Table 35: Antech (Mars). Products Portfolio

Table 36: Eurofins Ingenasa Basic Information And Sales Area

Table 37: Eurofins Ingenasa. Products Portfolio

Table 38: IDEXX Basic Information And Sales Area

Table 39: IDEXX. Products Portfolio

Table 40: Bio-Rad Basic Information And Sales Area

Table 41: Bio-Rad. Products Portfolio

Table 42: Thermo Fisher Scientific Basic Information And Sales Area

Table 43: Thermo Fisher Scientific. Products Portfolio

Table 44: Randox Basic Information And Sales Area

Table 45: Randox. Products Portfolio

Table 46: Idvet Basic Information And Sales Area

Table 47: Idvet. Products Portfolio

Table 48: Edan Instruments Basic Information And Sales Area

Table 49: Edan Instruments. Products Portfolio

Table 50: Micropointbio Basic Information And Sales Area

Table 51: Micropointbio. Products Portfolio

Table 52: Mnchip Basic Information And Sales Area

Table 53: Mnchip. Products Portfolio

Table 54: Seamaty Basic Information And Sales Area

Table 55: Seamaty. Products Portfolio

Table 56: Digifluidic Basic Information And Sales Area

Table 57: Digifluidic. Products Portfolio

Table 58: Mindrayanimal Basic Information And Sales Area

Table 59: Mindrayanimal. Products Portfolio

Table 60: Wondfo Biotech Basic Information And Sales Area

Table 61: Wondfo Biotech. Products Portfolio

Table 62: Dymind Basic Information And Sales Area

Table 63: Dymind. Products Portfolio

Table 64: Shenzhen Pukang Electronic Co.,Ltd. Basic Information And Sales Area

Table 65: Shenzhen Pukang Electronic Co.,Ltd.. Products Portfolio

Table 66: Genrui-bio Basic Information And Sales Area

Table 67: Genrui-bio. Products Portfolio

Table 68: Tecom-cn Basic Information And Sales Area

Table 69: Tecom-cn. Products Portfolio

Table 70: USTAR Basic Information And Sales Area

Table 71: USTAR. Products Portfolio

Table 72: Dawnsailbio Basic Information And Sales Area

Table 73: Dawnsailbio. Products Portfolio

Table 74: Quicking Basic Information And Sales Area

Table 75: Quicking. Products Portfolio

Table 76: Coyotebio Basic Information And Sales Area

Table 77: Coyotebio. Products Portfolio

Table 78: Anheal Basic Information And Sales Area

Table 79: Anheal. Products Portfolio

Table 80: Shenzhen Gangzhu Medical Technology Co.,Ltd. Basic Information And Sales Area

Table 81: Shenzhen Gangzhu Medical Technology Co.,Ltd.. Products Portfolio

Table 82: Sansure Biotech Basic Information And Sales Area

Table 83: Sansure Biotech. Products Portfolio

Table 84: Dian Diagnostics Basic Information And Sales Area

Table 85: Dian Diagnostics. Products Portfolio

Table 86: Global Market Value (USD Million) (2025-2032) By Application

Table 87: Global Market Share (%) By Application (2032)

Table 88: Global Market Value (USD Million) (2025-2032) By Types

Table 89: Global Market Share (%) By Types (2032)

Table 90: Global Animal IVD Market Value (USD Million) By Region

Table 91: Global Animal IVD Market Share (%) By Region (2025-2032)

Table 92: North America Market Value (USD Million) (2025-2032) By Country

Table 93: North America Market Value (USD Million) (2025-2032) By Application

Table 94: North America Market Value (USD Million) (2025-2032) By Types

Table 95: Europe Market Value (USD Million) (2025-2032) By Country

Table 96: Europe Market Value (USD Million) (2025-2032) By Application

Table 97: Europe Market Value (USD Million) (2025-2032) By Types

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 101: South America Market Value (USD Million) (2025-2032) By Country

Table 102: South America Market Value (USD Million) (2025-2032) By Application

Table 103: South America Market Value (USD Million) (2025-2032) By Types

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Animal IVD Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	3.80 million
Revenue forecast in 2033	7.68 million
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Heska; Zoetis; Antech (Mars); Eurofins Ingenasa; IDEXX; Bio-Rad; Thermo Fisher Scientific; Randox; Idvet; Edan Instruments; Micropointbio; Mnchip; Seamaty; Digifluidic; Mindrayanimal; Wondfo Biotech; Dymind; Shenzhen Pukang Electronic Co.,Ltd.; Genrui-bio; Tecom-cn; USTAR; Dawnsailbio; Quicking; Coyotebio; Anheal; Shenzhen Gangzhu Medical Technology Co.,Ltd.; Sansure Biotech; Dian Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Key analytical take-aways by application3 items

Clinical chemistry dominance is volume, not margin driven; price erosion of 3–5 % y-o-y is common.

Endocrinology immunoassays deliver the highest operating surplus per test, justifying R&D focus.

Molecular diagnostics is the fastest expanding slice of Animal IVD segmentation despite current <10 % share.

Animal IVD Segmentation Breakdown12 items

Application

Pet Hospital

Animal Husbandry and Veterinary System

Zoo

Research Institute Animal Experiment Center

Animal and Plant Quarantine Department

Others

Types

Immunodiagnosis

Clinical Biochemistry and Molecular Diagnosis

Hematology

Other

Regional Insights

Loading chart…

Competitive Landscape

Companies Strategy Snapshot6 items

IDEXX: premium pricing anchored by closed-channel reagent contracts

Zoetis: bolt-on acquisitions to widen companion-animal assay menu

Antech (Mars): vertical integration of reference labs and logistics

Eurofins Ingenasa: localized manufacturing for EU African swine fever tests

Thermo Fisher: OEM tie-ups to co-brand analyzers for emerging markets

Mindrayanimal: cost-leader strategy with region-specific cartridge bundles

Market Ecosystem

Reagent & consumable suppliers — supply antibodies, enzymes, and single-use plastics validated for companion and livestock assays

Platform OEMs — integrate optics, fluidics, and software into benchtop or POC analysers compliant with animal health regulations

Technology licensors — provide PCR, sequencing, or immunoassay IP that determines menu breadth and analytical performance

Authorised distributors — stock instruments, manage cold-chain logistics, and deliver local regulatory documentation to clinics and labs

Reference & contract labs — run high-throughput panels for producers, aggregating sample flows that shape assay demand forecasts

Veterinary software vendors — embed IVD results into EMRs, enabling longitudinal health tracking and billing integration

Regulatory agencies — set validation thresholds, batch-release protocols, and import permits, controlling market entry speed

Recent Industry Insights

Analyst Overview

Table of Contents